Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Sanofi launches voice-guided epinephrine auto-injector in US

Auvi-Q extends pharma company's interests in innovative devices

Sanofi Auvi-Q

Sanofi has launched a voice-guided epinephrine auto-injector Auvi-Q in the US to provide emergency treatment for life-threatening allergic reactions in people who are at risk for, or have a history of, anaphylaxis.

The first-of-its-kind device is the size and shape of a credit card and the thickness of a smart phone. It talks patients and caregivers step-by-step through the injection process. 

Anne Whitaker, president of North America Pharmaceuticals at Sanofi, said: "Patient feedback was a critical component to the development process for Auvi-Q.

"The availability of Auvi-Q represents an important step forward in our continued innovation to meet the needs of people at risk for anaphylaxis and their caregivers."

Up to six million Americans may be at risk for anaphylaxis caused by allergic reactions to the allergens contained in foods like nuts and shellfish, insect stings and certain medications.

For these people epinephrine can play a vital life-saving role, but surveys have found that some two-thirds of patients and caregivers do not carry their epinephrine auto-injectors as recommended.

Moreover, nearly half worry that others will not know how to use their, or their child's, epinephrine auto-injector correctly during an emergency.

Auvi-Q, which will be available through US pharmacies with a prescription from a healthcare provider, provides users with a range of audible and visual cues, including a five-second injection countdown and an alert light to signal when the injection is complete.

The technology underpinning the new device was licensed in November 2009 by Sanofi from Intelliject, which retained commercialisation rights for the product outside the US, and Auvi-Q was approved by the FDA in August last year.

The company will be hoping the launch of Auvi-Q will both boost its position in the allergy market and help its stated aim of becoming “a provider of healthcare solutions”.

Usually for a pharma product the Auvi-Q has won plaudits for its design, and was named at last month's CES Innovations 2013 Design and Engineering Awards as an honoree alongside technologies like Fitbit and Scanadu.

Auvi-Q also adds to a range of innovative devices in Sanofi's key therapy areas that include its iPhone blood glucose meter iBGStar and the AllStar reusable insulin pens for emerging markets.

6th February 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics